BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38334950)

  • 21. Imaging features to distinguish posterior fossa ependymoma subgroups.
    Leclerc T; Levy R; Tauziède-Espariat A; Roux CJ; Beccaria K; Blauwblomme T; Puget S; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Bolle S; Roux A; Pallud J; Provost C; Oppenheim C; Varlet P; Boddaert N; Dangouloff-Ros V
    Eur Radiol; 2024 Mar; 34(3):1534-1544. PubMed ID: 37658900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
    Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
    Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
    Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
    Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
    Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
    Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
    Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
    Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.
    Jünger ST; Andreiuolo F; Mynarek M; Dörner E; Zur Mühlen A; Rutkowski S; von Bueren AO; Pietsch T
    Childs Nerv Syst; 2020 Nov; 36(11):2693-2700. PubMed ID: 32474813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
    Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
    J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma.
    Fu R; Norris GA; Willard N; Griesinger AM; Riemondy KA; Amani V; Grimaldo E; Harris F; Hankinson TC; Mitra S; Ritzmann TA; Grundy RR; Foreman NK; Donson AM
    Neuro Oncol; 2023 Apr; 25(4):786-798. PubMed ID: 36215273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.
    Lummus SC; Donson AM; Gowan K; Jones KL; Vibhakar R; Foreman NK; Kleinschmidt-DeMasters BK
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28548702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
    Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
    Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.
    Puget S; Grill J; Valent A; Bieche I; Dantas-Barbosa C; Kauffmann A; Dessen P; Lacroix L; Geoerger B; Job B; Dirven C; Varlet P; Peyre M; Dirks PB; Sainte-Rose C; Vassal G
    J Clin Oncol; 2009 Apr; 27(11):1884-92. PubMed ID: 19289631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.
    Benesch M; Mynarek M; Witt H; Warmuth-Metz M; Pietsch T; Bison B; Pfister SM; Pajtler KW; Kool M; Schüller U; Pietschmann K; Juhnke BO; Tippelt S; Fleischhack G; Schmid I; Kramm CM; Vorwerk P; Beilken A; Classen CF; Hernáiz Driever P; Kropshofer G; Imschweiler T; Lemmer A; Kortmann RD; Rutkowski S; von Hoff K
    Oncologist; 2019 Sep; 24(9):e921-e929. PubMed ID: 30850560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).
    Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG
    Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
    Upadhyaya SA; Robinson GW; Onar-Thomas A; Orr BA; Billups CA; Bowers DC; Bendel AE; Hassall T; Crawford JR; Partap S; Fisher PG; Tatevossian RG; Seah T; Qaddoumi IA; Vinitsky A; Armstrong GT; Sabin ND; Tinkle CL; Klimo P; Indelicato DJ; Boop FA; Merchant TE; Ellison DW; Gajjar A
    Neuro Oncol; 2019 Oct; 21(10):1319-1330. PubMed ID: 30976811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.
    Tanrıkulu B; Danyeli AE; Özek MM
    Childs Nerv Syst; 2020 May; 36(5):941-949. PubMed ID: 32025869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosomal imbalances in clear cell ependymomas.
    Rickert CH; Korshunov A; Paulus W
    Mod Pathol; 2006 Jul; 19(7):958-62. PubMed ID: 16648869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
    Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment implications of posterior fossa ependymoma subgroups.
    Ramaswamy V; Taylor MD
    Chin J Cancer; 2016 Nov; 35(1):93. PubMed ID: 27846874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delineation of molecular characteristics in pediatric PFA ependymoma involving rare osseous and pulmonary metastases: A case report and literature review.
    Zhou M; Wang L; Sun P; Liu Y; Chen G; Zeng G
    Front Oncol; 2022; 12():1001118. PubMed ID: 36457507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.